spacer
home > ict > autumn 2017 > shredding paper
PUBLICATIONS
International Clinical Trials

Shredding Paper

The informed consent process represents the keystone in a
clinical trial, the space where science meets the patient. As
healthcare began to globalise in the 1990s and 2000s, process
and presentation flexibility became crucial. With technology
spreading around the globe, the defects and difficulties in the
use of text-only documents, reported internationally for 30
years, became even more apparent. Patients worldwide decreed
that text-only paper consent forms were confusing, hard to
and sometimes in different languages. Patients frequently
breezed through paper forms without truly understanding
the material and were surprised by aspects of the trial once it
started. This led to frustration and subjects often dropped out
of the consent process or the trial itself.

With the globalisation of clinical research, creating a flexible
system that works across international boundaries, yet respects
the differences of countries and regions, is imperative.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Eric Delente, President at DrugDev Patient Solutions, has more than 20 years of experience leading technical and creative teams in the design and implementation of numerous award-winning online science, healthcare and clinical research web applications. Most recently, he led SecureConsent, the industry’s definitive eConsent solution.
spacer
Eric Delente
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lesaffre Acquires Recombia Biosciences, a Biotechnology Company Specialized in High-Throughput Genome Editing and Synthetic Biology

Lesaffre, a global key player in the field of fermentation for nearly 170 years, today announces the acquisition of Recombia Biosciences, a biotechnology company based in the San Francisco Bay Area and founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. The partnership marked Lesaffre’s entry into the world of Synthetic Biology, considered to be one of the largest biotechnology opportunities of this decade.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement